-
2
-
-
84911474269
-
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii1-9
-
(2014)
Ann Oncol
, vol.25
, pp. iii1-iii9
-
-
Van Cutsem, E.1
Cervantes, A.2
Nordlinger, B.3
-
3
-
-
0031019918
-
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study
-
de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15
-
(1997)
J Clin Oncol
, vol.15
, pp. 808-815
-
-
de Gramont, A.1
Bosset, J.F.2
Milan, C.3
-
4
-
-
0024347268
-
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
-
Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18
-
(1989)
J Clin Oncol
, vol.7
, pp. 1407-1418
-
-
Poon, M.A.1
O'Connell, M.J.2
Moertel, C.G.3
-
5
-
-
42949150908
-
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
-
Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12
-
(2008)
J Clin Oncol
, vol.26
, pp. 2006-2012
-
-
Cassidy, J.1
Clarke, S.2
Díaz-Rubio, E.3
-
6
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
-
(2000)
J Clin Oncol
, vol.18
, pp. 2938-2947
-
-
de Gramont, A.1
Figer, A.2
Seymour, M.3
-
7
-
-
34249000361
-
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest
-
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6
-
(2007)
J Clin Oncol
, vol.25
, pp. 1670-1676
-
-
Falcone, A.1
Ricci, S.2
Brunetti, I.3
-
8
-
-
36048960109
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study
-
Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86
-
(2007)
J Clin Oncol
, vol.25
, pp. 4779-4786
-
-
Fuchs, C.S.1
Marshall, J.2
Mitchell, E.3
-
9
-
-
1842569206
-
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
-
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
-
(2004)
J Clin Oncol
, vol.22
, pp. 23-30
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
-
10
-
-
84871720057
-
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
-
Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37
-
(2013)
Lancet Oncol
, vol.14
, pp. 29-37
-
-
Bennouna, J.1
Sastre, J.2
Arnold, D.3
-
11
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
12
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
13
-
-
17844368327
-
The MAPK signalling pathways and colorectal cancer
-
Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6:322-7
-
(2005)
Lancet Oncol
, vol.6
, pp. 322-327
-
-
Fang, J.Y.1
Richardson, B.C.2
-
14
-
-
34047248571
-
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
-
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8
-
(2007)
Cancer Res
, vol.67
, pp. 2643-2648
-
-
Benvenuti, S.1
Sartore-Bianchi, A.2
Di Nicolantonio, F.3
-
15
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
-
16
-
-
33646228635
-
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
-
Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
-
(2006)
Cancer Res
, vol.66
, pp. 3992-3995
-
-
Lièvre, A.1
Bachet, J.B.2
Le Corre, D.3
-
17
-
-
0024376173
-
ras oncogenes in human cancer: a review
-
Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9
-
(1989)
Cancer Res
, vol.49
, pp. 4682-4689
-
-
Bos, J.L.1
-
18
-
-
84938748933
-
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials
-
Peeters M, Kafatos G, Taylor A, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer 2015;51:1704-13
-
(2015)
Eur J Cancer
, vol.51
, pp. 1704-1713
-
-
Peeters, M.1
Kafatos, G.2
Taylor, A.3
-
19
-
-
0032490124
-
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study
-
Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-84
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 675-684
-
-
Andreyev, H.J.1
Norman, A.R.2
Cunningham, D.3
-
20
-
-
84901813155
-
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)
-
Yoon HH, Tougeron D, Shi Q, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014;20:3033-43
-
(2014)
Clin Cancer Res
, vol.20
, pp. 3033-3043
-
-
Yoon, H.H.1
Tougeron, D.2
Shi, Q.3
-
21
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80
-
(2009)
J Clin Oncol
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
-
22
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72
-
(2009)
N Engl J Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
-
23
-
-
79960149283
-
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
-
Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 2011;29:2675-82
-
(2011)
J Clin Oncol
, vol.29
, pp. 2675-2682
-
-
Price, T.J.1
Hardingham, J.E.2
Lee, C.K.3
-
24
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
26
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
27
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
-
(2007)
J Clin Oncol
, vol.25
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
-
28
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
29
-
-
85006199550
-
An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab)+ best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC
-
Kim TW, Elme A, Kusic Z, et al. An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab)+ best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC. J Clin Oncol 2016;34:abstr 642
-
(2016)
J Clin Oncol
, vol.34
-
-
Kim, T.W.1
Elme, A.2
Kusic, Z.3
-
30
-
-
84899981129
-
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
-
Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15:569-79
-
(2014)
Lancet Oncol
, vol.15
, pp. 569-579
-
-
Price, T.J.1
Peeters, M.2
Kim, T.W.3
-
31
-
-
85006209285
-
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC)
-
Price TJ, Peeters M, Kim TW, et al. Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33:abstr 3586
-
(2015)
J Clin Oncol
, vol.33
-
-
Price, T.J.1
Peeters, M.2
Kim, T.W.3
-
32
-
-
79959337678
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
-
Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
-
(2011)
Lancet
, vol.377
, pp. 2103-2114
-
-
Maughan, T.S.1
Adams, R.A.2
Smith, C.G.3
-
33
-
-
84861432557
-
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
-
Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30:1755-62
-
(2012)
J Clin Oncol
, vol.30
, pp. 1755-1762
-
-
Tveit, K.M.1
Guren, T.2
Glimelius, B.3
-
34
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
35
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
-
Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
-
36
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Köhne, C.H.2
Láng, I.3
-
37
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
-
38
-
-
84925324704
-
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
-
Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692-700
-
(2015)
J Clin Oncol
, vol.33
, pp. 692-700
-
-
Van Cutsem, E.1
Lenz, H.J.2
Köhne, C.H.3
-
39
-
-
44249111440
-
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
-
Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9
-
(2008)
J Clin Oncol
, vol.26
, pp. 2311-2319
-
-
Sobrero, A.F.1
Maurel, J.2
Fehrenbacher, L.3
-
40
-
-
78149239651
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13
-
(2010)
J Clin Oncol
, vol.28
, pp. 4706-4713
-
-
Peeters, M.1
Price, T.J.2
Cervantes, A.3
-
41
-
-
84879786289
-
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
-
Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013;14:749-59
-
(2013)
Lancet Oncol
, vol.14
, pp. 749-759
-
-
Seymour, M.T.1
Brown, S.R.2
Middleton, G.3
-
42
-
-
84908520152
-
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)
-
Peeters M, Oliner KS, Price TJ, et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:abstr 3568
-
(2014)
J Clin Oncol
, vol.32
-
-
Peeters, M.1
Oliner, K.S.2
Price, T.J.3
-
43
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
-
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
von Weikersthal, L.F.2
Decker, T.3
-
44
-
-
84905870196
-
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
-
Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240-7
-
(2014)
J Clin Oncol
, vol.32
, pp. 2240-2247
-
-
Schwartzberg, L.S.1
Rivera, F.2
Karthaus, M.3
-
45
-
-
84907027361
-
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
-
Venook AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014;32:abstr LBA3
-
(2014)
J Clin Oncol
, vol.32
-
-
Venook, A.P.1
Niedzwiecki, D.2
Lenz, H.J.3
-
46
-
-
84960438729
-
501ocalgb/Swog 80405: phase III trial of irinotecan/5-Fu/leucovorin (folfiri) or oxaliplatin/5-Fu/leucovorin (mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with expanded Ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mcrc)
-
Lenz H, Niedzwiecki D, Innocenti F, et al. 501ocalgb/Swog 80405: phase III trial of irinotecan/5-Fu/leucovorin (folfiri) or oxaliplatin/5-Fu/leucovorin (mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with expanded Ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mcrc). Ann Oncol 2014;25:mdu438
-
(2014)
Ann Oncol
, vol.25
-
-
Lenz, H.1
Niedzwiecki, D.2
Innocenti, F.3
-
47
-
-
84911460699
-
Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306)
-
Heinemann V, Modest DP, von Weikersthal LF, et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306). Ann Oncol 2014;25:ii117
-
(2014)
Ann Oncol
, vol.25
-
-
Heinemann, V.1
Modest, D.P.2
von Weikersthal, L.F.3
-
48
-
-
84937211692
-
CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy
-
Venook A, Niedzwiecki D, Lenz H, et al. CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy. Ann Oncol 2014;25:mdu438
-
(2014)
Ann Oncol
, vol.25
-
-
Venook, A.1
Niedzwiecki, D.2
Lenz, H.3
-
49
-
-
0035444798
-
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
-
Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-6
-
(2001)
Br J Cancer
, vol.85
, pp. 692-696
-
-
Andreyev, H.J.1
Norman, A.R.2
Cunningham, D.3
-
50
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
-
51
-
-
84867117207
-
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
-
Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30:3570-7
-
(2012)
J Clin Oncol
, vol.30
, pp. 3570-3577
-
-
Tejpar, S.1
Celik, I.2
Schlichting, M.3
-
52
-
-
84875742535
-
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab
-
Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013;31:759-65
-
(2013)
J Clin Oncol
, vol.31
, pp. 759-765
-
-
Peeters, M.1
Douillard, J.Y.2
Van Cutsem, E.3
-
53
-
-
85006211711
-
The AGITG ICECREAM Study: The irinotecan cetuximab evaluation and cetuximab response evaluation amongst patients with a G13D mutation-analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation
-
Segelov E, Thavaneswaran S, Waring P. The AGITG ICECREAM Study: The irinotecan cetuximab evaluation and cetuximab response evaluation amongst patients with a G13D mutation-analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. Eur J Cancer 2015;51:S726
-
(2015)
Eur J Cancer
, vol.51
, pp. S726
-
-
Segelov, E.1
Thavaneswaran, S.2
Waring, P.3
-
54
-
-
22244472992
-
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
-
Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9
-
(2005)
Cancer Res
, vol.65
, pp. 6063-6069
-
-
Samowitz, W.S.1
Sweeney, C.2
Herrick, J.3
-
55
-
-
77953688634
-
Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis
-
Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010;127:367-80
-
(2010)
Int J Cancer
, vol.127
, pp. 367-380
-
-
Zlobec, I.1
Bihl, M.P.2
Schwarb, H.3
-
56
-
-
84859885193
-
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features
-
Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012;36:744-52
-
(2012)
Am J Surg Pathol
, vol.36
, pp. 744-752
-
-
Pai, R.K.1
Jayachandran, P.2
Koong, A.C.3
-
57
-
-
84893164570
-
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome
-
Saridaki Z, Tzardi M, Sfakianaki M, et al. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. PLoS One 2013;8:e84604
-
(2013)
PLoS One
, vol.8
-
-
Saridaki, Z.1
Tzardi, M.2
Sfakianaki, M.3
-
58
-
-
84899918816
-
Mutational analysis and clinical correlation of metastatic colorectal cancer
-
Russo AL, Borger DR, Szymonifka J, et al, Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014;120:1482-90
-
(2014)
Cancer
, vol.120
, pp. 1482-1490
-
-
Russo, A.L.1
Borger, D.R.2
Szymonifka, J.3
-
59
-
-
67649652208
-
BRAF mutation in metastatic colorectal cancer
-
Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9
-
(2009)
N Engl J Med
, vol.361
, pp. 98-99
-
-
Tol, J.1
Nagtegaal, I.D.2
Punt, C.J.3
-
60
-
-
84925105975
-
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis
-
Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015;51:587-94
-
(2015)
Eur J Cancer
, vol.51
, pp. 587-594
-
-
Pietrantonio, F.1
Petrelli, F.2
Coinu, A.3
-
61
-
-
84862026304
-
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials
-
Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75
-
(2012)
Eur J Cancer
, vol.48
, pp. 1466-1475
-
-
Bokemeyer, C.1
Van Cutsem, E.2
Rougier, P.3
-
62
-
-
84951810474
-
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
-
Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 2015;33:4032-8
-
(2015)
J Clin Oncol
, vol.33
, pp. 4032-4038
-
-
Kopetz, S.1
Desai, J.2
Chan, E.3
-
63
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
-
Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
64
-
-
84864340896
-
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
-
Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:773-81
-
(2012)
Lancet Oncol
, vol.13
, pp. 773-781
-
-
Infante, J.R.1
Fecher, L.A.2
Falchook, G.S.3
-
65
-
-
84940908895
-
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers
-
Hong DS, Morris VK, El Osta BE, et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 2015;33:abstr 3511
-
(2015)
J Clin Oncol
, vol.33
-
-
Hong, D.S.1
Morris, V.K.2
El Osta, B.E.3
-
66
-
-
84939864059
-
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
-
Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015;373:726-36
-
(2015)
N Engl J Med
, vol.373
, pp. 726-736
-
-
Hyman, D.M.1
Puzanov, I.2
Subbiah, V.3
-
67
-
-
84925133542
-
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC)
-
Tabernero J, Chan E, Baselga J, et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol 2014;32:abstr 3518
-
(2014)
J Clin Oncol
, vol.32
-
-
Tabernero, J.1
Chan, E.2
Baselga, J.3
-
68
-
-
84927604543
-
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
-
Yaeger R, Cercek A, O'Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015;21:1313-20
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1313-1320
-
-
Yaeger, R.1
Cercek, A.2
O'Reilly, E.M.3
-
69
-
-
84951745408
-
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
-
Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol 2015;33:4023-31
-
(2015)
J Clin Oncol
, vol.33
, pp. 4023-4031
-
-
Corcoran, R.B.1
Atreya, C.E.2
Falchook, G.S.3
-
70
-
-
85006205259
-
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
-
Schellens JH, van Geel R, Bendell JC, et al. Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Cancer Res 2015;75:CT136
-
(2015)
Cancer Res
, vol.75
, pp. CT136
-
-
Schellens, J.H.1
van Geel, R.2
Bendell, J.C.3
-
71
-
-
84944718228
-
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
-
Atreya CE, Van Cutsem E, Bendell JC, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Oncol 2015;33:103
-
(2015)
Ann Oncol
, vol.33
, pp. 103
-
-
Atreya, C.E.1
Van Cutsem, E.2
Bendell, J.C.3
-
72
-
-
84895794537
-
Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors
-
Das Thakur M, Stuart DD. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. Clin Cancer Res 2014;20:1074-80
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1074-1080
-
-
Das Thakur, M.1
Stuart, D.D.2
-
73
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
-
74
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
-
75
-
-
84937696509
-
S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC)
-
Kopetz S, McDonough S, Morris VK, et al. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33:abstr TPS790
-
(2015)
J Clin Oncol
, vol.33
-
-
Kopetz, S.1
McDonough, S.2
Morris, V.K.3
-
76
-
-
84891629487
-
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
-
Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014;50:57-63
-
(2014)
Eur J Cancer
, vol.50
, pp. 57-63
-
-
Loupakis, F.1
Cremolini, C.2
Salvatore, L.3
-
77
-
-
84953856186
-
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
-
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16:1306-15
-
(2015)
Lancet Oncol
, vol.16
, pp. 1306-1315
-
-
Cremolini, C.1
Loupakis, F.2
Antoniotti, C.3
-
78
-
-
33846595479
-
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
-
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27
-
(2006)
J Clin Oncol
, vol.24
, pp. 5313-5327
-
-
Locker, G.Y.1
Hamilton, S.2
Harris, J.3
-
79
-
-
65349189958
-
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
-
Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6
-
(2009)
J Clin Oncol
, vol.27
, pp. 2091-2096
-
-
Allegra, C.J.1
Jessup, J.M.2
Somerfield, M.R.3
-
80
-
-
85006226633
-
-
National Comprehensive Cancer Network. NCCN Guidelines: Colon Cancer, Version 2. 2016. Available online: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
-
(2016)
NCCN Guidelines: Colon Cancer, Version 2
-
-
-
81
-
-
34247278727
-
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
-
Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9
-
(2007)
Br J Cancer
, vol.96
, pp. 1166-1169
-
-
Di Fiore, F.1
Blanchard, F.2
Charbonnier, F.3
-
82
-
-
84877130883
-
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
-
Tougeron D, Lecomte T, Pagès JC, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013;24:1267-73
-
(2013)
Ann Oncol
, vol.24
, pp. 1267-1273
-
-
Tougeron, D.1
Lecomte, T.2
Pagès, J.C.3
-
83
-
-
84929463919
-
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy
-
Laurent-Puig P, Pekin D, Normand C, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 2015;21:1087-97
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1087-1097
-
-
Laurent-Puig, P.1
Pekin, D.2
Normand, C.3
-
84
-
-
85043654463
-
Clinical validation of real-time PCR and SNaPshot methods in comparison to NGS for KRAS and NRAS Mutation Detection in colorectal cancer at Genia Laboratories (Uruguay)
-
Marques JM, Repetto L, Guggeri L, et al. Clinical validation of real-time PCR and SNaPshot methods in comparison to NGS for KRAS and NRAS Mutation Detection in colorectal cancer at Genia Laboratories (Uruguay). J Clin Oncol 2015;33:e22121
-
(2015)
J Clin Oncol
, vol.33
-
-
Marques, J.M.1
Repetto, L.2
Guggeri, L.3
-
85
-
-
84879240684
-
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
-
Valtorta E, Misale S, Sartore-Bianchi A, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013;133:1259-65
-
(2013)
Int J Cancer
, vol.133
, pp. 1259-1265
-
-
Valtorta, E.1
Misale, S.2
Sartore-Bianchi, A.3
-
86
-
-
84937207523
-
Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer
-
Lee MS, Overman MJ, Maru DM, et al. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. J Clin Oncol 2014;32:abstr 3633
-
(2014)
J Clin Oncol
, vol.32
-
-
Lee, M.S.1
Overman, M.J.2
Maru, D.M.3
-
87
-
-
80052591747
-
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
-
Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86
-
(2011)
Sci Transl Med
, vol.3
-
-
Yonesaka, K.1
Zejnullahu, K.2
Okamoto, I.3
-
88
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-73
-
(2013)
Cancer Discov
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
Corso, S.2
Bertotti, A.3
-
89
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
-
De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603
-
(2011)
Lancet Oncol
, vol.12
, pp. 594-603
-
-
De Roock, W.1
De Vriendt, V.2
Normanno, N.3
-
90
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
-
91
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
92
-
-
84944079826
-
The genomic landscape of response to EGFR blockade in colorectal cancer
-
Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-7
-
(2015)
Nature
, vol.526
, pp. 263-267
-
-
Bertotti, A.1
Papp, E.2
Jones, S.3
-
93
-
-
84908431348
-
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
-
Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-80
-
(2014)
Cancer Discov
, vol.4
, pp. 1269-1280
-
-
Misale, S.1
Di Nicolantonio, F.2
Sartore-Bianchi, A.3
-
94
-
-
84873360893
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19:657-67
-
(2013)
Clin Cancer Res
, vol.19
, pp. 657-667
-
-
Mao, M.1
Tian, F.2
Mariadason, J.M.3
-
95
-
-
84878066430
-
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
-
Coffee EM, Faber AC, Roper J, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013;19:2688-98
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2688-2698
-
-
Coffee, E.M.1
Faber, A.C.2
Roper, J.3
-
96
-
-
84933040790
-
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
-
Ahronian LG, Sennott EM, Van Allen EM, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov 2015;5:358-67
-
(2015)
Cancer Discov
, vol.5
, pp. 358-367
-
-
Ahronian, L.G.1
Sennott, E.M.2
Van Allen, E.M.3
-
97
-
-
84934925449
-
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial
-
Heinemann V, Modest DP, Fischer von Weikersthal L, et al. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 2014;32:abstr 3600
-
(2014)
J Clin Oncol
, vol.32
-
-
Heinemann, V.1
Modest, D.P.2
Fischer von Weikersthal, L.3
|